Deborah Andrews is recorded as Chief Accounting Officer at Staar Surgical Co (STAA) since March 17, 2025, CEO and CFO at Staar Surgical Co (STAA) and Board Member at Lineage Cell Therapeutics, Inc. (LCTX) since January 1, 2014. The newest filing on record that lists Deborah Andrews as CFO at Staar Surgical Co (STAA) is dated May 4, 2026. The newest filing on record that lists Deborah Andrews as Board Member at Lineage Cell Therapeutics, Inc. (LCTX) is dated April 29, 2026. Staar Surgical Co reported in an 8-K filed August 6, 2026 that Deborah Andrews was appointed Executive Vice President (EVP), effective August 4, 2026. Staar Surgical Co reported in an 8-K filed February 2, 2026 that Deborah Andrews was appointed Interim Co-Chief Executive Officer, effective February 1, 2026. Staar Surgical Co reported in an 8-K filed June 25, 2025 that Deborah Andrews was appointed Chief Financial Officer, effective June 25, 2025. Equibles holds 6 filed executive changes naming Deborah Andrews; each is listed under recent activity with its source filing. The proxy statement of Staar Surgical Co reports total compensation of $2,582,411 for Deborah Andrews in fiscal 2025, including a base salary of $810,173. Disclosed compensation is on record for 4 fiscal years. Deborah Andrews has spoken on 5 earnings calls across 1 company, most recently for Staar Surgical Co on November 4, 2026. Staar Surgical Co is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Lineage Cell Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Staar Surgical Co includes Stephen C. Farrell (CEO), Stephen Farrell (CEO and Board Member), Thomas "Tom" G. Frinzi (CEO) and 7 others.
“Deborah Andrews, who has served since February 2026 as Interim Co-CEO alongside Mr. Foust, will cease serving as Interim Co-CEO and continue to serve as Chief Financial Officer and has additionally been appointed Executive Vice President (“EVP”) as of the Effective Date.”
Staar Surgical Co Form 8-K, filed August 6, 2026
· Read the filing
“On February 1, 2026, the Board of Directors (the "Board") of STAAR Surgical Company (the "Company") appointed Warren Foust and Deborah Andrews as Interim Co-Chief Executive Officers, effective February 1, 2026 (the "Effective Date").”
Staar Surgical Co Form 8-K, filed February 2, 2026
· Read the filing
Deborah Andrews on recent calls
“I'll review our third quarter results, including the impact of the prior year's deferred sales item, and discuss our margin outlook, operating expenses, and cash position.”
“I'll provide a brief financial summary and then we'll move to Q&A. Second quarter net sales were $93.5 million compared to $44.3 million in the prior year quarter, which as a reminder was impacted by minimal China shipments while distributors worked through excess inventory.”
“I'm pleased to join you on today's call, and I'm proud to lead the STAR organization with you as co-CEO. As Warren said, we took a number of steps in 2025 to reduce our costs and improve our profitability.”
“Let me start with some high level comments on sales, profitability, and margins. Historically, the company has reported net sales and ICL sales separately. As sales attributed to our IOLs and other products have decreased over time, the difference between our net sales and ICL sales is now quite small.”
“I'll begin with a financial review, summarizing our top line results before going into more detail on the income statement. STAAR reported net sales of $35.2 million for the first quarter of 2020, reflecting an 8% increase over the $32.6 million from the same period last year.”
